NCT03380039: Phase 1 - Clinical Study of CAR-BCMA T Cells in Patients With RRMM
- Active, not recruiting
- Dec 6, 2017
- 1 min read
Updated: Apr 25, 2022
NCT03380039: Phase 1 - Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma
A single arm, open-label pilot study is designed to determine the safety, efficacy and cytokinetics of CAR-BCMA T cells in patients with BCMA-positive refractory or relapsed multiple myeloma.
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Collaborator: CARsgen Therapeutics Co., Ltd.
ClinicalTrials.gov Identifier: NCT03380039
Clinical Study of Redirected Autologous T Cells With a BCMA-targeted Chimeric Antigen Receptor in Patients With Refractory or Relapsed Multiple Myeloma
Click here for details on Clinicaltrials.gov
Genetic: CAR-BCMA T cells
Drug: Fludarabine
Drug: Cyclophosphamide
703.Adoptive Immunotherapy: Mechanisms and New Approaches| November 13, 2019
Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma
China, Shanghai
Xin Hua Hospital of Shanghai Jiao Tong University of Medicine Shanghai,
Shanghai, China, 200092
